Pharmacokinetic variability of voriconazole and N-oxide voriconazole measured as therapeutic drug monitoring

Xenobiotica

Volumn 40, Issue 10, 2010, Pages 701-706

  Eiden, Céline ^a   Cociglio, Maryléne ^a   Hillaire Buys, Dominique ^a   Eymard Duvernay, Sabrina ^b   Ceballos, Patrice ^a   Fegueux, Nathalie ^a   Peyrire, Hélène ^a,b,c  

^a LAPEYRONIE HOSPITAL   (France)

^b UNIVERSITÉ DE MONTPELLIER   (France)

^c UNIV MONTPELLIER   (France)

Author keywords

metabolic ratio; N oxide voriconazole; therapeutic drug monitoring; voriconazole

Indexed keywords

ANTIFUNGAL AGENT; DRUG METABOLITE; N OXIDE VORICONAZOLE; UNCLASSIFIED DRUG; VORICONAZOLE;

ADOLESCENT; ADULT; ARTICLE; BRAIN DISEASE; CHOLESTASIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIVER FUNCTION TEST; MALE; RISK BENEFIT ANALYSIS; SIDE EFFECT; SKIN TOXICITY; TREATMENT DURATION; TREATMENT RESPONSE; VISUAL HALLUCINATION;

ADULT; ANTIFUNGAL AGENTS; DRUG MONITORING; FEMALE; HUMANS; MALE; MIDDLE AGED; PYRIMIDINES; TRIAZOLES;

EID: 77956567635     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2010.503814     Document Type: Article

References (17)

1. Ascioglu S, Rex JH, de Pauw B et al. (2002). Defning opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 34:7-14.
2. Brüggemann RJ, Alfenaar JW, Blijlevens NM, Billaud EM, Kosterink JG, Verweij PE, Burger DM. (2009). Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis 48:1441-1458.
3. Eiden C, Mathieu O, Peyrière H, Hillaire-Buys D, Cociglio M. (2008) Simultaneous quantifcation of voriconazole and its N-oxide metabolite in human plasma by an easy and rapid isocratic LC method with UV detection. Chromatographia 67:275-280.
4. Ikeda Y, Umemura K, Kondo K, Sekiguchi K, Miyoshi S, Nakashima M. (2004). Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status. Clin Pharmacol Ter 75:587-588.
5. Imhof A, Schaer DJ, Schanz U, Schwarz U. (2006). Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. Swiss Med Wkly 136:739-742.
6. Matsumoto K, Ikawa K, Abematsu K, Fukunaga N, Nishida K, Fukamizu T, Shimodozono Y, Morikawa N, Takeda Y, Yamada K. (2009). Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with diferent CYP2C19 genotypes. Int J Antimicrob Agents 34:91-94.
7. Meletiadis J, Chanock S, Walsh TJ. (2008). Defning targets for investigating the pharmacogenomics of adverse drug reactions to anti-fungal agents. Pharmacogenomics 9:561-584.
8. Mulanovich V, Lewis RE, Raad II, Kontoyiannis DP. (2007). Random plasma concentrations of voriconazole decline over time. J Infect 55:e129-e130.
9. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. (2008). Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efcacy and safety outcomes. Clin Infect Dis 46:201-211.
10. Purkins L, Wood N, Ghahramani P, Greenhalgh K, Allen MJ, Kleinermans D. (2002). Pharmacokinetics and safety of vorico-nazole following intravenous-to oral-dose escalation regimens. Antimicrob Agents Chemother 46:2546-2553.
11. Rofey SJ, Cole S, Comby P, Gibson D, Jezequel SG, Nedderman AN, Smith DA, Walker DK, Wood N. (2003). Te disposition of vorico-nazole in mouse, rat, rabbit, guinea pig, dog, and human. Drug Metab Dispos 31:731-741.
12. Scholz I, Oberwittler H, Riedel KD, Burhenne J, Weiss J, Haefeli WE, Mikus G. (2009). Pharmacokinetics, metabolism and bioavail-ability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. Br J Clin Pharmacol 68:906-915.
13. Smith J, Safdar N, Knasinski V, Simmons W, Bhavnani SM, Ambrose PG, Andes D. (2006). Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 50:1570-1572.
14. Tan K, Brayshaw N, Tomaszewski K, Troke P, Wood N. (2006). Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol 46:235-243.
15. US Food and Drug Administration (2001). Briefng document for voriconazole. Basic Pharmacokinetics of Voriconazole N-oxide US Food and Drug Administration, Washington D.C. Available in 2009 at: http://www.fda.gov/ohrms/ dockets/ac/01/briefng/3792b2.htm.
16. Weiss J, Ten Hoevel MM, Burhenne J, Walter-Sack I, Hofmann MM, Rengelshausen J, Haefeli WE, Mikus G. (2009). CYP2C19 genotype is a major factor contributing to the highly variable pharmacoki-netics of voriconazole. J Clin Pharmacol 49:196-204.
17. Wood N, Tan K, Purkins L, Layton G, Hamlin J, Kleinermans D, Nichols D. (2003). Efect of omeprazole on the steady-state pharmacokinetics of voriconazole. Br J Clin Pharmacol 56 Suppl 1:56-61. (Pubitemid 37491735)